Skip to main content

Advertisement

Table 3 Number of tender points and tender joints

From: Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

Parameters Baseline (n = 16) 6 weeks (n = 15) 10 weeks (n = 13) 18 weeks (n = 14) 32 weeks (n = 11)
Tender points 4.1 ± 5.6 2.0 ± 3.1 2.1 ± 3.4 1.6 ± 2.9 2.4 ± 3.3
Tender joints 4.0 ± 7.5 1.0 ± 1.8 1.1 ± 1.6 1.2 ± 1.9 0.3a ± 0.5
  1. Results are given as mean ± standard deviation. aDenotes statistical significance of the observed median change-from-baseline value with P ≤ 0.05 by Wilcoxon signed rank test. Almost all patients had no swollen joints at baseline or subsequent time points.